Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model

Fig. 1

CXCR4 expression in U87MG cell line. a CLSM analyses of U87MG cells stimulated (+) or not (-) with CXCL12 (100 ng/ml) and treated (+) with peptide R (10 μM) or Plerixafor (10 μM) or left untreated (−). After 48 or 72 h of culture cells were stained with anti-CXCR4 mAb (green) prior to (UNFIXED, top panel) or after (FIXED, bottom panel) fixation with 3 % PFA. Nuclei were stained with DAPI (shown in blue). Scale bars, 15 μm. b Representative western blot analysis of CXCR4 detection in U87MG cells processed after 24, 48 and 72 h of treatments as described in (a). β-actin was used as loading control. Histograms represent the relative fold change of CXCR4 expression normalized to β-actin, obtained with densitometric analyses of western blot bands (Image J software). Means ± SD of n = 3 independent experiments. Statistical analyses were performed with one-way ANOVA, * P = 0.0042

Back to article page